University of Massachusetts Chan Medical School, Department of Microbiology and Physiological Systems, Program of Microbiome Dynamics, Worcester, Massachusetts, USA.
Infect Immun. 2022 May 19;90(5):e0058321. doi: 10.1128/iai.00583-21. Epub 2022 May 11.
Inflammatory bowel diseases (IBD), namely, Crohn's disease (CD) and ulcerative colitis (UC), are lifelong and incurable chronic inflammatory diseases affecting 6.8 million people worldwide. By 2030, the prevalence of IBD is estimated to reach 1% of the population in Western countries, and thus there is an urgent need to develop effective therapies to reduce the burden of this disease. Microbiome dysbiosis is at the heart of the IBD pathophysiology, and current research and development efforts for IBD treatments have been focused on gut microbiome regulation. Diet can shape the intestinal microbiome. Diet is also preferred over medication, is safe, and has been proven to be an effective strategy for the management of IBD. Therefore, although often overlooked, dietary interventions targeting the microbiome represent ideal treatments for IBD. Here, I summarize the latest research on diet as a treatment for IBD from infancy to adulthood, compile evidence of the mechanisms of action behind diet as treatment, and, lastly, provide insights into future research focusing on culturally tailored diets for ethnic minority groups with increased incidence of IBD yet underrepresented in nutrition research.
炎症性肠病(IBD),即克罗恩病(CD)和溃疡性结肠炎(UC),是一种影响全球 680 万人的终生不可治愈的慢性炎症性疾病。到 2030 年,预计西方国家的 IBD 患病率将达到人口的 1%,因此迫切需要开发有效的治疗方法来减轻这种疾病的负担。微生物组失调是 IBD 病理生理学的核心,目前针对 IBD 治疗的研究和开发工作都集中在肠道微生物组的调节上。饮食可以塑造肠道微生物组。饮食也优于药物,是安全的,并且已被证明是管理 IBD 的有效策略。因此,尽管常常被忽视,但针对微生物组的饮食干预措施是 IBD 的理想治疗方法。在这里,我总结了从婴儿期到成年期饮食作为 IBD 治疗的最新研究,编译了饮食作为治疗作用机制的证据,并最后提供了关于针对少数族裔的文化适应性饮食的未来研究的见解,这些少数族裔的 IBD 发病率增加,但在营养研究中代表性不足。